

Attorney Docket No.: 6413.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

Confirmation No.: 6226

Application No.: 10/614,233

Group Art Unit: 1614

Filed: July 7, 2003

Examiner: Henley III, Raymond J.

For: Pharmaceutical Use of Boronic Acids and Esters Thereof

**CERTIFICATE OF FACSIMILE TRANSMISSION
UNDER 37 CFR 1.8(a)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment/Response to final Office Action/Advisory Action (18 pages)
2. Petition and Fee for Extension of Time (in duplicate)

is being deposited with the United States Patent and Trademark Office via fax no. 571-273-0575 on April 8, 2005, to the attention of Examiner Raymond J. Henley III.


Rosemarie R. Wilk-Orescan, Esq.
(Name of person transmitting paper)


(Signature of person transmitting paper)

Attorney Docket No.: 6413.204-US
Ebdrup et al.
Application No.: 10/614,233 Filed July 7, 2003

Please charge the required fee, estimated to be \$1020, with this petition and credit any overpayments to Novo Nordisk Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



Date: April 8, 2005

Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE